Stéphane Bancel

Stéphane Bancel became CEO of Moderna in 2011 when the company was a pre-clinical startup with zero revenue and a bold hypothesis: that messenger RNA (mRNA) could be programmed to instruct human cells to produce virtually any therapeutic protein. The COVID-19 pandemic proved this hypothesis on the grandest possible stage — Moderna's mRNA vaccine was developed in just 42 days and went on to generate over $18 billion in annual revenue at peak, becoming one of the most commercially successful pharmaceutical products in history. Now Bancel faces the challenge of the "post-COVID cliff" — as pandemic vaccine revenue has declined dramatically, Moderna must demonstrate that its mRNA platform can deliver multiple commercial products. The pipeline includes a combined COVID-flu vaccine, an RSV vaccine (already approved), a CMV vaccine, and most ambitiously, individualized neoantigen therapy (INT) for cancer — a personalized cancer vaccine that is showing promising results in melanoma and non-small cell lung cancer trials in partnership with Merck. Bancel's execution on pipeline clinical trials (particularly cancer and combination vaccines), revenue diversification beyond COVID, and cash burn management during the transition period are the critical drivers of Moderna's stock.